Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
ISH-0613 in Systemic Lupus Erythematosus: NCT07516639 Clinical Landscape Report 2026
18 September 2026
NCT07516639 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CHT-105 in Lupus Nephritis: NCT07517536 Clinical Landscape Report 2026
18 September 2026
NCT07517536 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CAR 70-BCMA CAR-T Cells(The General Hospital of Western Theater Command) in Plasma Cell Neoplasms: NCT07519187 Clinical Landscape Report 2026
18 September 2026
NCT07519187 clinical landscape for Plasma Cell Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
![[68Ga] Pentixafor in Multiple Myeloma: CTRI/2026/04/108288 Clinical Landscape Report 2026](https://synapse-static.patsnap.com/strapi-static/Blog_cover_06_34c12a0757.jpg)
9 min read
[68Ga] Pentixafor in Multiple Myeloma: CTRI/2026/04/108288 Clinical Landscape Report 2026
18 September 2026
CTRI/2026/04/108288 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Adalimumab biosimilar(Jiangsu Chia-tai Tianqing Pharmaceutical Co. Ltd.) in Plaque psoriasis: NCT07529925 Clinical Landscape Report 2026
18 September 2026
NCT07529925 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tacrolimus in Dermatitis, Atopic: NCT07519174 Clinical Landscape Report 2026
18 September 2026
NCT07519174 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ustekinumab in Psoriasis: NCT07529236 Clinical Landscape Report 2026
18 September 2026
NCT07529236 clinical landscape for Psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pamlectabart tismanitin in Plasma cell dyscrasia: NCT07529782 Clinical Landscape Report 2026
18 September 2026
NCT07529782 clinical landscape for Plasma cell dyscrasia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Levofloxacin in Acute Myeloid Leukemia: NCT07528417 Clinical Landscape Report 2026
18 September 2026
NCT07528417 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
REGN-20423 in Dermatitis, Atopic: NCT07527923 Clinical Landscape Report 2026
18 September 2026
NCT07527923 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
VC-005 in Dermatitis, Atopic: NCT07533851 Clinical Landscape Report 2026
18 September 2026
NCT07533851 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BR101 (Byterna therapeutics) in Relapse multiple myeloma: NCT07537049 Clinical Landscape Report 2026
18 September 2026
NCT07537049 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.